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INTRODUCTION
The MYC proto-oncogene family includes MYC that encodes c-Myc, MYCN that encodes N-Myc, and MYCL that encodes L-Myc. Myc proteins are bHLHZ transcription factors that regulate genes involved in growth and proliferation (Dang, 2012) . MYC genes are normally induced in response to mitogenic stimulation. However, oncogenic activation occurs through events that lead to overexpression of Myc proteins and failure to downregulate expression in response to appropriate physiological signals.
Deregulated Myc family proteins transcriptionally reprogram cellular metabolism to facilitate the macromolecular synthesis required for increased cell growth and proliferation. For example, c-Myc induces aerobic glycolysis (the Warburg effect) by enhancing glucose uptake and lactate production as well as providing glycolytic intermediates for nucleotide, amino acid, and lipid biosynthesis (reviewed in Dang, 2013; Vander Heiden et al., 2009) . While these processes divert carbon from the tricarboxylic acid (TCA) cycle and mitochondria, c-Myc also regulates genes that enhance glutamine uptake and processing to fuel the TCA cycle (Gao et al., 2009; Wise et al., 2008; Yuneva et al., 2007) ; moreover, c-Myc stimulates mitochondrial activity through induction of TFAM and other nuclear-encoded mitochondrial genes (Li et al., 2005) . Recent work demonstrates that c-Myc promotes lipid metabolism during cell cycle entry (Morrish et al., 2010) and lymphomagenesis (Eberlin et al., 2014) . Importantly, cells transformed by deregulated MYC genes are highly sensitive to metabolic stress induced by nutrient withdrawal or inhibition of metabolic pathways (reviewed in Dang, 2011) .
Myc proteins function within a transcription factor network ( Figure 1A ; Conacci-Sorrell et al., 2014) . These proteins form heterodimers with the small bHLHZ protein Max and bind to E-Box sequences in DNA. Myc transcriptional activity is antagonized by Mxd family proteins that compete with Myc for both Max and E-Box binding. Expression of Mxd proteins often correlates with cell cycle exit, growth arrest, and/or differentiation (Hooker and Hurlin, 2006) . In addition, a parallel, Myc-like network exists See also Figure S1 and Table S1 . centered around Mlx (Billin and Ayer, 2006) . Mlx heterodimerizes with either MondoA or carbohydrate response element binding protein (ChREBP) . MondoA associates with the mitochondrial outer membrane, where it can sense both glycolytic intermediates such as glucose 6-phosphate and mitochondrial metabolites (Han and Ayer, 2013; Kaadige et al., 2009; Sloan and Ayer, 2010) . Metabolites promote nuclear localization of cytoplasmic MondoA protein, activating transcription of genes involved in glucose metabolism (reviewed in O'Shea and Ayer, 2013) . Moreover, Mlx heterodimerizes with a subset of Mxd family proteins, thereby linking the Mlx and Max branches into a larger transcription factor network ( Figure 1A ; Billin et al., 1999; Meroni et al., 2000) . This network is conserved throughout metazoan evolution (McFerrin and Atchley, 2011) , indicative of collaboration between the nutrient-sensing Mondo and the nutrient-utilizing Myc branches of the network.
Because environmental context can determine survival of cells transformed by Myc family proteins, we reasoned that the extended Myc-network is likely to be important in integrating environmental cues and promoting tumor survival.
RESULTS

Synthetic Lethal Interaction between Deregulated Myc and MondoA Loss of Function
To determine whether deregulated Myc depends on other transcription factors within the Myc superfamily, we carried out a targeted siRNA screen of the extended Myc network. The screen used murine fibroblasts with doxycycline (dox)-inducible c-Myc expression (clone P3C1). Induction of c-Myc (c-Myc-ON) resulted in increased proliferation and apoptosis as well as loss of the differentiation marker Thy1.2 (Eischen et al., 2001; Evan et al., 1992; Sridharan et al., 2009 ; Figures S1A-S1C available online). Our most striking finding was that knockdown of MondoA and, to a lesser extent, its obligate dimerization partner Mlx, revealed a synthetic lethal (SL) effect in c-Myc-ON compared to c-Myc-OFF cells (Figures 1B and S1D) . Knockdown of ChREBP had no effect because it is not expressed in P3C1 cells ( Figure S1E ).
To extend our observations on the dependency of Myc overexpressing cells on MondoA/Mlx, we examined mouse embryonic fibroblasts (MEFs) bearing homozygous deletions of either Mlxip, which encodes MondoA, or Mlx (D.E.A., P.F.C., P.A.C., and R.N.E., unpublished data). Compared to the parental wild-type cells, both Mlxip À/À and Mlx À/À primary MEFs display reduced viability and higher levels of apoptosis upon c-Myc overexpression. Mlxip deletion also enhances c-Myc mediated apoptosis in Large-T antigen immortalized fibroblasts, suggesting a p53-independent apoptotic process ( Figure S1F and see below). We next examined the effects of MondoA knockdown (KD) in a panel of human cell types, in each case comparing cells without and with overexpression of Myc. We found that KD of MondoA using siRNA (siMonA) significantly reduces survival of the P493-6 human B cell line expressing c-Myc (Figures 1C and S1G) . This SL effect was also observed with siMonA in human neural stem cells (CB660) overexpressing c-Myc (CB660+c-Myc) as well as their immortalized derivatives lacking p53 and RB tumor suppressors (I-CB660+c-Myc) or transformed by the additional expression of activated H-Ras (T-CB660+c-Myc) (Hubert et al., 2013) ( Figure 1D ). Control cells were insensitive to siMonA, indicating that MondoA loss of function specifically inhibits survival of cells with deregulated c-Myc. MondoA silencing also inhibits the growth of colon cancer cell line HCT116, hepatocellular carcinoma cell line HEPG2, and ovarian cancer cell line TOV1112D, all of which express high levels of c-Myc (Figure S1H) . Importantly, siRNA against Mlx also elicited the same response in all cells tested (data not shown).
MYCN amplification is observed in approximately 25% of human neuroblastomas and correlates with poor outcome (Brodeur, 2003; Huang and Weiss, 2013) . Therefore, we examined the requirement of deregulated N-Myc for MondoA using a retroviral vector to achieve stable MondoA KD (Kaadige et al., 2009) Figure 1E ). Reduction of MondoA protein levels following knockdown is shown in Figure S1I . We did not detect changes in Myc protein levels after MondoA silencing, indicating that loss of MondoA does not inhibit cell proliferation by reducing Myc expression (see Figures S2A, S2H-S2J ). However, c-Myc or N-Myc induction enhances MondoA mRNA (Figures S1J and S1K) and protein levels in both cytoplasm and nucleus (Figures 1F and S1L) in Tet21N and P493-6 cells. This is consistent with our chromatin immunoprecipitation data for N-Myc (Figure S1M) , as well as data from the ENCODE database (not shown), showing that c-Myc binds the MondoA promoter region.
Because MondoA would be expected to compete with several Mxd transcription factors for binding to Mlx, we surveyed expression levels of Mxd1, Mxd4, and Mnt upon N-Myc activation in Tet21N cells. N-Myc overexpression reduces c-Myc and Mxd4 protein expression while increasing Max, Mlx, and MondoA proteins ( Figure S1N ). Consistent with this, the expression of the MondoA target gene Txnip increases upon N-Myc activation (Figure S1O) . Our experiments suggest that deregulated Myc alters the Max/Mlx network to enhance MondoA/Mlx transcriptional activity and requires MondoA/Mlx for survival and proliferation.
MondoA Suppresses Myc-Induced Apoptosis in Neuroblastoma
To study functional interactions between N-Myc and MondoA, we used the Tet21N cell line . Tet21N cells in the presence of dox (N-Myc-OFF) express endogenous c-Myc and proliferate but are nontumorigenic. Following dox withdrawal, N-Myc is induced (N-Myc-ON) in Tet21N cells and cells display increased proliferation and growth in soft agar and as xenografts (Kim et al., 2007; Wasylishen et al., 2014) . We assessed proliferation, the cell cycle, and apoptosis in Tet21N cells under four conditions: siCtrl or siMonA with and without dox. Transient siMonA blocked proliferation of the Tet21N N-Myc-ON cells, while having little or no effect on the N-Myc-OFF cells, compared to siCtrl (Figure 2A) . Each of the four individual siRNAs efficiently silences the expression of MondoA and only inhibits the growth of N-Myc-ON cells, indicating the phenotype we observed is a result of MondoA inactivation ( Figure S2A ). While siMonA marginally reduces the percentage of cells in S phase independent of N-Myc levels, there is a striking accumulation of sub-G1 cells in the siMonA N-Myc-ON cells, indicative of apoptosis ( Figures 2B and 2C ). MondoA KD also blocked (legend continued on next page) expression of its target gene TXNIP (Figures 2D and S2B; Stoltzman et al., 2008) , and suppressed mechanistic target of rapamycin (mTOR) activity ( Figure 2D ). We also detected increased levels of p53 and p21 with siMonA, which are further increased after N-Myc activation ( Figure 2D ). Our data suggest MondoA suppresses stress associated with N-Myc deregulation and ensures cell cycle progression and survival.
The tumorigenic potential of Tet21N cells stably expressing either shCtrl or shMonA was first assessed by soft agar assays. While shCtrl N-Myc-ON cells form numerous colonies, shMonA N-Myc-ON cells formed fewer and smaller colonies (Figures 2E and 2F) . MondoA silencing also reduced the growth of N-Mycamplified cell lines in soft agar ( Figure 2F ). Importantly, the dimin- We also performed subcutaneous xenograft of Tet21N N-Myc-ON cells stably expressing either shCtrl or shMonA. We observed reduced tumor size and tumor weight of cells expressing shMonA (Figures 2G and 2H) due to both loss of proliferation and activation of apoptosis (Figures 2I and S2G) . Both N-Myc protein stability in the Tet21N cells ( Figure S2H ) and abundance in lysates derived from the xenografts ( Figure S2I ) are independent of MondoA. Very similar SL interactions were obtained in the P493-6 human lymphoma line (Figures 1C and S2J) . We conclude that MondoA is broadly required for downstream functions of Myc in tumor growth and survival in vitro and in vivo.
N-Myc and MondoA Coordinately Regulate Expression of Growth-Promoting Genes To find out if MondoA loss affects N-Myc functions, we compared transcriptional changes induced by N-Myc activation in the presence or absence of MondoA . Overall, the N-Myc-induced changes in gene expression are highly correlated independent of MondoA levels (Figure S3B) . Moreover, MondoA knockdown does not alter the levels of histone H4 acetylation observed upon N-Myc induction ( Figure S3D ), indicating MondoA functions in conjunction with Myc, but does not fundamentally alter N-Myc activity.
However, whereas the general transcriptional activity of N-Myc is similar in the presence or absence of MondoA, the magnitude of change for both N-Myc activated and repressed genes is significantly attenuated in the siMonA condition compared to siCtrl ( Figure 3B ). Interestingly, after normalizing gene expression values to the siMonA/N-Myc-OFF condition and comparing the relative contributions of N-Myc and MondoA alone, we observe a trend in which both transcription factors similarly up-or downregulate a large number of genes in common ( Figure S3E ). Specifically, we identified 553 and 587 genes significantly upregulated and downregulated, respectively, when both N-Myc and MondoA are present ( Figures 3A and 3C) .
To assess the functional relevance of these transcriptional profiles, we used gene ontology analysis of the gene sets individually and cooperatively regulated by N-Myc and MondoA (false discovery rate [FDR] adjusted p < 0.05). N-Myc primarily drives the expression of genes promoting cell proliferation and growth ( Figure 3D , white bars). However, N-Myc also requires MondoA to maximally upregulate a large number of genes involved in these processes ( Figure 3D , striped bars). The relative expression levels of all cooperatively upregulated genes among the four conditions are shown in Figure 3E . Interestingly, among these are several genes critical for nucleotide biosynthesis, amino acid metabolism and transport, mitochondrial biogenesis and function, and the TCA cycle.
We also find that silencing of MondoA independent of N-Myc leads to lower expression of genes involved in oxidation-reduction reactions, cholesterol and steroid metabolism, as well as components of the endoplasmic reticulum, extracellular matrix, peroxisomes, and lysosomes ( Figure 3F , gray bars). In particular, MondoA depletion leads to a strong decrease in SREBP1 and SCD expression, as well as a lesser reduction in FASN and PCK2, which encode enzymes involved in lipid and glucose metabolism, respectively ( Figure 3G ). Hence, N-Myc, individually and in cooperation with MondoA, controls the expression of a large set of genes involved in proliferation, metabolism, and growth, whereas MondoA additionally regulates complementary pathways such as lipid and sterol biogenesis.
There may be several mechanisms for the cooperative transcriptional regulation by N-Myc and MondoA. To determine whether both factors co-occupy promoters of coregulated genes we tested if N-Myc and MondoA bind to the TXNIP promoter, a bona fide MondoA target that contains three noncanonical E-boxes. Results show that both factors bind to the TXNIP promoter and that maximum binding of both N-Myc and MondoA requires the simultaneous presence of both factors ( Figure S3F and Discussion).
Expression of Myc/MondoA-Dependent Genes Involved in Metabolism Is Required for Survival of Neuroblastoma Cells
Our data show that a significant fraction of genes regulated by N-Myc and MondoA are linked to metabolic activities ( Figures   3D-3G ). We used qRT-PCR and immunoblot analyses to assess expression of a subset of genes under the four conditions used in the microarray study, focused on those affecting multiple metabolic pathways, and found that all genes analyzed require either N-Myc/MondoA or MondoA for maximal expression ( Figures 4A  and S4A ). The expression of these genes was similarly affected by silencing of the MondoA heterodimerization partner Mlx in Tet21N cells, consistent with the notion that changes in expression we observed are a direct consequence of the lack of MondoA-Mlx heterodimers ( Figure S4B ). Interestingly, silencing of either MondoA or Mlx results in the loss of expression of both proteins, indicating that heterodimerization promotes complex stability ( Figure S4B ).
Because we also observe synthetic lethality in P493-6 B cells, we queried http://www.oncomine.org for data sets of B cell malignancies (Basso et al., 2005; Zhang et al., 2013) . We found a correlation between c-Myc, Mlx (in one data set), and many target genes in both Burkitt lymphoma and other B-cell malignancies as well as neuroblastoma (Table S1 ) (Janoueix-Lerosey et al., 2008; Wang et al., 2006) , consistent with the notion of similar transcriptional reprogramming of metabolism by the coordinate action of Myc-Max and MondoA-Mlx arms of the network. Using MondoA or Mlx null primary MEFs, we found that expression of Slc1A5 and Tomm20, both of which are coregulated in the Tet21N cells, depends on both Myc and MondoA ( Figure S4C ), implying that c-Myc and MondoA display a similar mode of coregulation in primary cells.
We also confirmed that N-Myc requires both 25 mM glucose and MondoA to fully activate the expression of the glutamine (Gln) transporter Slc1A5, suggesting that glucose-responsive transcriptional activity of MondoA coordinates glucose availability with Gln uptake ( Figure 4B ). To determine whether cellular metabolism is affected by MondoA knockdown in the Tet21N cells, we measured carbon source uptake using radiolabeled Gln or 2-deoxyglucose. A notable increase in Gln uptake was observed upon N-Myc activation, which was inhibited by shMonA treatment in both the N-Myc-ON Tet21N cells (Figure 4C) and in c-Myc overexpressing MEFs ( Figure S4D ). Consistent with the glucose dependency of Slc1A5 expression, maximal N-Myc-induced Gln uptake was also glucose-dependent ( Figure S4E ). In contrast, N-Myc expression or MondoA knockdown produced only a modest increase in 2-deoxyglucose uptake and no significant difference was observed between control and SL conditions ( Figure S4F ). Furthermore, although extracellular acidification rate was not significantly affected by N-Myc expression or shMonA ( Figure S4G ), MondoA loss prevented the N-Myc driven increase in Gln-dependent oxygen consumption rate ( Figure 4D ), confirming that MondoA loss in cells expressing N-Myc results in fundamental changes in cellular Gln metabolism.
Decreased expression of transporter genes may account, at least in part, for diminished Gln uptake and viability upon MondoA loss (Figures 4A and S4A) . As previously shown, knockdowns of either Gln importer Slc1A5 or antitransporter Slc3A2 resulted in decreased activity of mTOR, as measured by ribosomal protein S6 phosphorylation (p-RpS6) ( Figure 4E ) (Durá n et al., 2012; Nicklin et al., 2009 ). However, only Slc1A5 silencing reduced Gln uptake, arguing that loss of Slc3A2 does not affect cell viability and mTOR signaling by preventing Gln uptake ( Figure S4H ). Importantly, while overexpression of Slc1A5 enhances Gln uptake ( Figure S4I ), neither Slc1A5 nor Slc3A2 overexpression rescues cell viability ( Figure 4F ). Therefore, reduced Gln uptake is not solely responsible for the observed SL phenotype.
Loss of MondoA attenuates the expression of genes involved in other metabolic pathways; therefore, we asked how the individual KD of coregulated or MondoA-dependent genes influences Tet21N cell survival. As shown in Figure 4G , siRNAs against 15 out of 21 selected targets were significantly more efficient at killing cells overexpressing N-Myc. Depletion of a subset of these targets in CB660 human NSCs confirmed that the single gene KD phenotype is Myc-specific in different cell lines ( Figure S4J ).
Inhibition of Myc/MondoA-Dependent Genes Induces P53-Independent Synthetic Lethality with Deregulated Myc
Because the activity of mTOR and p53 are often inversely correlated under stress conditions (Feng and Levine, 2010), we eval- Figure S4 and Table S1. uated whether the individual silencing of other Myc SL metabolic genes affects p-RpS6 and p21 levels, as indicators of mTOR and p53 activity, respectively. While only inactivation of Pfas, Cbs, or Pck2 results in mTOR inhibition, all knockdowns induce p21 to varying levels ( Figure 5A ). This suggests that p53 senses the activity of multiple Myc-and MondoA-regulated pathways.
To evaluate the response of Tet21N cells to p53 activation, we used the MDM2 antagonist Nutlin-3a, which strongly induces both p53 and p21 and inhibits growth of both N-Myc-OFF and -ON cells ( Figures 5B and 5C ). However, Nutlin-3a treatment does not stimulate significant caspase activity in siCtrl cells, regardless of N-Myc status ( Figure 5C ), indicating that p53 activation promotes cell cycle arrest but not apoptosis in these cells. Conversely, loss of MondoA alone promotes caspase activity in N-Myc-ON cells, which is further enhanced by Nutlin-3a treatment ( Figure 5C ). This implies that MondoA silencing in N-Myc-ON cells induces apoptosis and that p53 activation only contributes to apoptosis following loss of MondoA. Importantly, we observe caspase activation only when N-Myc is overexpressed. Furthermore, complete knockdown of p53 in the N-Myc-ON cells only partially rescues viability with siMonA (Figure 5D) . Moreover, while p53 KD re-establishes RpS6 phosphorylation, it does not reestablish expression of Myc and MondoA target genes Pfas and Tomm20, indicating that the reduction in mTOR activity is a consequence of apoptosis and not the cause of the SL phenotype ( Figure S5A ). Moreover, HCT116 cells (Figures 5E and S5B) , or CB660 cells ( Figure S4J ) and MEFs Figure 4F ) or BCL2 were transfected with siCtrl or siMonA and viable cells were enumerated by trypan blue exclusion after 4 days (left) and western blot for Bcl2. Shown are mean and SD (n = 3). See also Figure S6 .
overexpressing c-Myc ( Figure S5C ), are equally sensitive to loss of MondoA, Mlx, or a number of critical Myc/MondoA targets, independent of p53 status. In addition, siMonA also results in the loss of Slc1A5, Pfas and Tomm20 expression and decreased Gln uptake independent of p53 in HCT116 cells (Figures S5D and S5E) , confirming that MondoA loss promotes apoptosis, at least in part, through a p53-independent mechanism. We also find that loss of MondoA ( Figure 5F ) or Mlx ( Figure S5F ) leads to downregulation of the prosurvival Bcl2 protein and promotes the appearance of the proapoptotic, truncated forms of Bid and Bax (tBid and tBax) and cleaved Parp, only in N-Myc-ON cells. These data indicate that N-Myc overexpression is required to promote apoptosis in the absence of MondoA through an intrinsic apoptotic pathway. However, enforced expression of Bcl2 was not sufficient to rescue viability in N-Myc-ON, siMonA cells ( Figure 5G ). These results prompted us to search for alternative MondoA-dependent metabolic pathways required for N-Myc-induced tumorigenesis.
Metabolic Profiling Reveals that N-Myc and MondoA Coordinately Regulate Anaplerotic and Cataplerotic Reactions of the Tricarboxylic Acid Cycle
We used LC-MS based metabolomic analysis to survey 139 soluble metabolites representing precursors and intermediates of major anabolic and catabolic pathways (see Supplemental Experimental Procedures). As shown in Figure 6A , we detected significant changes in metabolite abundance among the four conditions. Metabolite set enrichment analysis reveals that N-Myc activation broadly modifies the cellular metabolic profile, promotes profound changes in amino acid metabolism and results in enhanced abundance of precursors for de novo purine and lipid biosynthesis ( Figure 6B ; blue bars). Importantly, the majority of metabolite set enrichment analysis categories enriched by N-Myc induction display diminished significance upon siMonA treatment in our SL condition ( Figure 6B , orange bars). Consistent with the observed cooperative transcriptional regulation of metabolic genes, we observe that maximal enrichment of certain metabolites, such as the nucleotide sugar ribose-5-phosphate and the isoprenoid geranyl-pyrophosphate depends on both N-Myc and MondoA. We also observe diminished levels of glutamate (Glu) and malate (Mal) and a 5-fold increase in citrate (Cit) upon MondoA silencing ( Figure S6A and data not shown). These data indicate alterations in the TCA cycle as a result of mitochondrial dysfunction, consistent with our observations of diminished mitochondrial content and activity, and enhanced reactive oxygen species production ( Figures  S6B and S6C) .
Because we observed diminished Gln uptake and alterations in abundance of TCA cycle intermediates, we directly tested how Gln metabolism is modified by N-Myc and MondoA. We used a gas chromatography-mass spectrometry (GC-MS) method (Du et al., 2013) to trace the contribution of uniformly labeled 13 C 5 -Gln to Glu, a-ketoglutarate (aKG), Mal, Cit, pyruvate (Pyr), and lactate (Lac). We chose 24 hr labeling to account for metabolites upstream and downstream of the TCA cycle. ) to Glu (m+5), aKG (m+5), Mal (m+4) but, paradoxically not TCA-derived Cit (m+4). We did not detect 13 C 5 -Gln contributing to either Pyr or Lac (data not shown), indicating that Gln is filling the TCA and not being converted to Pyr, via cytosolic malic enzyme, then, via lactate dehydrogenase A, to Lac.
To directly test if reduced glutaminolysis and mitochondrial activity are responsible for the synthetic lethal phenotype, we evaluated the response of Tet21N cells to both nutrient withdrawal and metabolic perturbing agents (Table S2 ). These cells are both glucose-and Gln-dependent, sensitive to common glutaminolysis perturbing agents, such as the nonspecific transaminase inhibitor aminooxyacetate (Szabo et al., 2013; Wise et al., 2008) , the OXPHOS complex I inhibitor metformin, or the Pck1/ Pck2 inhibitor 3-mercaptopicolinic acid, and sensitive to oxidative stress induced by H 2 O 2 . We also tested pathway-specific metabolites for their ability to rescue loss of viability induced by treatment with inhibitors or siMonA. While none of the rescue agents can substitute for glucose or Gln, each specific inhibitor can be rescued by metabolites downstream of the inhibited pathway. Similar sensitivities to these inhibitors were observed in HCT116 cells, independent of p53 status (Table S2 and data not shown).
Importantly, none of the agents used to rescue impaired glutaminolysis, such as dmKG, Pyr, or enforced Slc1A5 or Bcl2 expression (Wise et al., 2008; Yuneva et al., 2007 ) is sufficient to rescue loss of MondoA (Table S2 and data not shown). Therefore, we ruled out a solely anaplerotic defect, and interrogated pathways downstream of the TCA cycle. As noted, Cit accumulates by 6-fold in the SL condition, as confirmed by GC-MS of total Cit ( Figure 6D ). Because Cit is produced from aKG either through the TCA cycle (producing m+4 Cit) or via an isocitrate dehydrogenase-mediated reductive carboxylation (producing m+5 Cit) ( Figure S6D ), we quantified m+5 Cit by GC-MS. We find a dramatic reduction in the m+5 Cit fraction under the SL condition ( Figure S6E ), indicating that, while the fate of Glnderived aKG is modified under our four conditions, the increased Cit content is not due to enhanced synthesis. Thus the marked accumulation of Cit could result from its diminished downstream utilization for de novo fatty acid or isoprenoid biosynthesis. Consistent with this hypothesis, we observed that loss of MondoA results in the downregulation of Srebp1, Fasn, and Scd, (Figure 4A ) all of which participate in the lipid biosynthesis pathway. Because Cit can be converted to acetyl-coA for de novo fatty acid synthesis ( Figure S6D ), we tested if Glnderived carbons contribute to lipid and if loss of MondoA impairs lipid biosynthesis. To this end, we used a lipid extraction protocol and GC-MS (Metallo et al., 2012) for tracing Gln-derived carbons to palmitate (C16:0) in the free fatty acid pool 48 hr after the addition of 13 C 5 -Gln. While N-Myc cooperates with MondoA to provide Gln as anaplerotic substrate to generate Cit, MondoA is further required to convert Cit into fatty acids because the total fraction of labeled palmitate (sum of m+2(N) palmitate) drops from about 20% to less than 15% of the pool upon MondoA silencing, independent of N-Myc ( Figures 6E and S6F) . Consistent with loss of Fasn expression, the fraction of labeled palmitate (m+4 to m+12) is significantly diminished ( Figure 6E) .
Deletion of Mlx in MEFs expressing endogenous Myc also leads to decreased expression of MondoA, Fasn, and other targets and reduced lipid content, but does not induce apoptosis (legend continued on next page) ( Figures S6G-S6J , and data not shown). Therefore diminished de novo fatty acid biosynthesis observed in the synthetic lethal condition is not a consequence of apoptosis but the metabolic response to the loss of MondoA-Mlx transcriptional activity and target gene expression.
To confirm the dependency of N-Myc-overexpressing cells on lipid biosynthesis for viability, we tested the sensitivity of Tet21N cells to the Fasn inhibitor C75 and the farnesyl diphosphate synthase inhibitor zoledronic acid (ZOL), which blocks geranylpyrophosphate production. Consistent with the siRNA results, N-Myc-overexpressing cells are significantly more sensitive to these inhibitors and there is no effect on viability of N-Myc-OFF cells when treated with the half-maximal inhibitory concentration of N-Myc-ON cells ( Figure S6K ). Furthermore, C75, but not ZOL, treatment synergizes with siMonA to hyperactivate caspase ( Figures 6F and S6L) , suggesting a sensitization to loss of FASN activity and consistent with decreased flux into palmitate. Similarly, siRNA-mediated silencing of Fasn or Scd enhances apoptosis in N-Myc-ON cells ( Figure S6M ). In addition, while the effect of ZOL treatment can be rescued by the downstream metabolite geranylgeraniol (Table S2) , this metabolite fails to rescue loss of viability in siMonA N-Myc-ON cells, indicating that inhibition of the isoprenoid pathway is not the causal event of our SL phenotype. Because C75 treatment can be rescued by oleate (C18:1) (Table S2) , we tested if oleate can rescue viability of siMonA N-Myc-ON cells. As shown in Figures 6G,  6H , and S6N, oleate suppresses activation of stress upon siMonA treatment and partially restores cell viability, thus placing the failure of lipid biosynthesis upstream of the cascade of stress-inducing events leading to the SL phenotype.
A Subset of Synthetic Lethal Genes Correlates with Poor Outcome in Several Cancers
Our data indicate that Myc and MondoA coordinately and independently enhance the expression of multiple metabolic genes to promote tumorigenesis ( Figure 7A ). If so, high expression of several of these genes in human cancers would be predicted to correlate with poor prognosis. Using the cumulative expression of MLXIP, CAD, TFAM, CBS, SCD, PFAS, SLC3A2, and SLC1A5, we calculated the overall survival of patients with different types of cancer and found that, in most cases, patients with high expression of the signature (top 20%, red) have poorer prognosis compared to those with low expression (bottom 20%, blue; the remaining 60% are shown in gray) ( Figure 7B ). However, while the difference between high-and low-expressing gene signatures is significant in neuroblastoma, liver hepatocellular carcinoma and lung squamous cell carcinoma and lung adenocarcinoma, it is only marginally significant in acute myeloid leukemia and colon adenocarcinoma and not significant in breast invasive carcinoma. This reflects the inherent heterogeneity of cancer and it is consistent with a recent report demonstrating that c-Myc overexpression elicits distinct metabolic programs in different tissues (Yuneva et al., 2012) .
DISCUSSION
Proliferation and metabolism are precisely coordinated processes during normal cell growth and division and are frequently deregulated in cancer. A unique property of the Max/Mlx network is its capacity to sense and respond to mitogenic signals and nutrient availability (Diolaiti et al., 2014; O'Shea and Ayer, 2013) . In this study, we provide evidence that the MondoA-Mlx heterodimer is required for Myc-driven transcriptional reprogramming of cellular metabolism and tumor growth. We show that MondoA/Mlx coordinates glucose sensing with Gln utilization and subsequent downstream biosynthesis required for Myc to promote hyperproliferation. Previous work has demonstrated a critical role for Gln in survival of Myc-driven cancers (Dang, 2011; Qing et al., 2012; Shachaf et al., 2007; Wise et al., 2008; Yuneva et al., 2007) . Here, we show that MondoA loss suppresses Myc-induced Gln uptake, Gln-dependent mitochondrial activity, and Gln-derived lipid biosynthesis, thus resulting in apoptosis. In support of our findings, MondoA was reported to be overexpressed in acute lymphoblastic leukemia, and its silencing prevents tumor cell growth (Wernicke et al., 2012 ). The SL phenotype described here places MondoA atop a transcriptional cascade that coordinately regulates multiple metabolic pathways critical for Myc-driven tumor survival.
Impairment of Myc/MondoA downstream metabolic effectors identified in this study has permitted us to define SL interactions specific to deregulated Myc. These include those involved in glucose, amino acid, nucleotide, mitochondrial function, and lipid metabolism. While Myc's connection with, and dependency upon, enhanced glycolysis, glutaminolysis, and mitochondrial activity are well known, a role for Pck2, a gluconeogenic enzyme, reveals a requirement of Myc for a bidirectional pathway. Recent reports demonstrating the necessity for Pck2 activity in both lung and breast cancer cells under nutrient limitation (Leithner et al., 2014; Mé ndez-Lucas et al., 2014) are consistent with MondoAMlx function as a nutrient-responsive factor to regulate survival.
We also observed impairment of lipid metabolism in our SL condition. While the MondoA family member ChREBP has been linked to glucose-derived lipogenesis in cancer cells (Tong et al., 2009 ), ChREBP has not been reported to alter glutaminolysis and its requirement for Myc-driven tumorigenesis remains untested. Our data support nonredundant roles for MondoA and ChREBP, as siRNA against MondoA (as well against Mlx) kills ChREBP-expressing cells.
Multiple studies have shown that inhibition of Acaca, Fasn, or Scd activity (Zaidi et al., 2013) See also Figure S6 and Table S2. 2013) attenuate cancer cell growth. Interestingly, we find that oleate partially rescues these insults as well as apoptosis due to MondoA suppression in cells with high Myc levels. Our study reveals the importance of lipogenesis in Myc-dependent metabolic reprogramming and provides a rationale for the clinical evaluation of lipogenesis inhibitors in Myc-driven malignancies. This is highly relevant in light of the recent report of altered lipidomic profiles induced by Myc in human lymphomas (Eberlin et al., 2014) Importantly, in contrast to all other Myc network members, Mondo proteins are ligand activated, because they sense glucose-6-phosphate and other glycolytic intermediates (McFerrin and Atchley, 2012; Peterson et al., 2010; Stoltzman et al., 2008) . Blocking the ability of MondoA to respond to glucose may represent a therapeutic strategy targeting Mycdriven tumors. In addition, a small molecule inhibitor of c-MycMax heterodimerization has been described (Wang et al., 2007) , indicating the feasibility of developing inhibitors of Mondo-Mlx heterodimerization.
Previous studies have clearly established functional antagonism between Myc and Mxd/Mnt proteins in the control of cell behavior (Hooker and Hurlin, 2006) . However, recent work demonstrating a role for Mnt in Myc-driven tumor progression (Link et al., 2012) , in conjunction with our report describing Myc-MondoA transcriptional synergy, suggests a more complex scenario in which an imbalance among network members promotes apoptosis.
How do N-Myc and MondoA cooperate to promote the transcription of their metabolic gene targets? One possibility involves simultaneous binding of both N-Myc and MondoA to promoters containing multiple E-boxes for maximal gene expression. Binding of c-Myc and either MondoA or ChREBP to the LDHA and HKII (Sans et al., 2006) or PKLR (Zhang et al., 2010) promoters has been described and we demonstrate that both N-Myc and MondoA bind to the TXNIP promoter. We also show that N-Myc activation promotes Mondo-Mlx activity by altering the expression of MondoA and other network members competing for the common heterodimerization partner Mlx. Conversely, loss of MondoA may inhibit N-Myc transcriptional activity by altering chromatin at metabolic target gene promoters to abrogate N-Myc transcriptional amplification (Lin et al., 2012; Nie et al., 2012) . Moreover, in the absence of MondoA, the Mxd and Mnt proteins may heterodimerize with Mlx and actively repress N-Myc/ MondoA target genes. These mechanisms are not mutually exclusive and may operate in a cell type-and promoter-specific manner.
Although much attention has been focused on Myc because of its oncogenic activity, we propose that a full understanding of Myc biology in both physiological and pathological contexts will require an understanding of the biology and dynamics of the Max/Mlx network as a whole.
EXPERIMENTAL PROCEDURES
A complete list of all techniques and reagents, such as enzyme inhibitors, retroviral, and lentiviral vectors and in vitro functional assay are listed in the Supplemental Experimental Procedures.
Xenograft
We resuspended 1 3 10 6 Tet21N cells in growth factor reduced, phenol redfree BD Matrigel (Becton Dickinson) that was subcutaneously injected into the flanks of nude athymic (nu/nu) mice (n = 10). Tumor volume was measured every 2-3 days and mice were killed when tumor burden reached a total volume of 2.5 cm 3 . Tumors were dissected and aliquots were either frozen in 
Gene Expression Analysis
Whole genome expression analysis was performed using Illumina HumanHT-12 v4 Expression BeadChip. Sample processing was performed at the Fred Hutchinson Cancer Research Center Genomics Facility and data were submitted to Gene Expression Omnibus (accession number of data set: GSE55538). For details about data statistical analysis, see below.
Metabolomic Profiling
Cell processing: 48 hr after transfection, 1 3 10 6 cells were plated in a sixwell plate. After 24 hr, culture media were aspirated, cells were washed twice in ice-cold water, and lysed in 1.5 ml of ice-cold 9:1 methanol:chloroform with the plates placed on dry ice (approximately À75 C) to quench metabolism.
After 5 min, cells were scraped and transferred into 1.5 ml tubes. Lysates were centrifuged at 13,000 revolutions per minute for 10 min and supernatants were transferred to new vials and dried using a Speedvac at room temperature. After reconstituting the dried samples in water and 1% formic acid, they were subjected to liquid chromatography-MS analysis (see Supplemental Experimental Procedures). Metabolite levels were normalized to cell number from parallel plates. For details about data statistical analysis, see below.
Statistical Analysis
Statistical significance of all in vitro experiments was calculated by using Graphpad Prism software with either a Student's t test for comparisons of only two conditions or ANOVA and a Bonferroni correction for multiple comparisons. Gene expression data were run in triplicate with quantile normalized and log-transformed values. Significance was determined by Benjamin Hotchberg FDR-adjusted p < 0.05 according to the lumi package using R version 3.0.1 (Du et al., 2008) . Gene ontology enrichment was reported for categories satisfying Benjamin Hotchberg adjusted p < 0.05 from the DAVID boinformatic database (Huang et al., 2009) . Metabolite data were normalized to the N-Myc OFF and siCtrl condition with log-transformed Z scores. Metabolite pathway enrichment was performed using Metaboanalyst (Xia et al., 2012) with metabolite sets having FDR-corrected p < 0.05 deemed significant. Both gene and metabolite heatmaps show median Z scores of each triplicate sample using Cluster and TreeView (Eisen et al., 1998) .
Kaplan-Meier Survival Curves
Kaplan Meier curves were calculated for gene expression data obtained for neuroblastoma (Oberthuer et al., 2006) as well as breast invasive carcinoma, lung squamous cell carcinoma and lung adenocarcinoma, colon adenocarcinoma, acute myeloid leukemia, and liver hepatocellular carcinoma reported by The Cancer Genome Browser (Lopez-Bigas N et al., 2013) for The Cancer Genome Atlas (additional details in Supplemental Experimental Procedures). Chromatography Conditions: Dried samples were reconstituted in 100 µL of 5 mM ammonium acetate in 95% water/5% acetonitrile + 0.5% acetic acid, and filtered through 0.45 µm PVDF filters (Phenomenex, Torrance, CA) prior to LC--MS analysis.
The LC system consisted of of two Agilent 1260 binary pumps, an Agilent 1260 auto--sampler and Agilent 1290 column compartment containing a column--switching valve (Agilent Technologies, Santa Clara, CA). Each sample was injected twice, 10 µL for analysis using negative ionization mode and 2 µL for analysis using positive ionization mode. Both chromatographic separations were performed in reverse phase (RP) on Thermo Accucore PFP columns (150 x 2.1 mm, 2.6 µm particle size, Thermo Fisher Scientific Inc., Waltham, MA). The flow rate was 0.250 mL/min, auto--sampler temperature was kept at 4 C, and the column compartment was set at 40 C. were derived with N--tert--butyldimethylsilyl--N--methyltrifluoroacetamide before measured by GC/MS as previously described (Du et al., 2013 ). An Agilent 15 °C/min. The ion source was held 230 °C, and quadrupole at 150 °C. Mass spectra between m/z 100--600 were collected under scanning mode. Abundances of ion between m/z 270--286 were extracted by Agilent Chemstation software for palmitate isotopomers. The natural abundance of isotopes was corrected using the software IsoCor (Du et al., 2013) .
Kaplan--Meier Survival Curves
The gene signature used in calculating survival curves was developed in order to individual genes within the top and bottom expression groups was calculated using a two--sided t--test with p value <0.01.
